CD274 and cancer: Immunotherapies that use antibodies directed to inhibitory immune checkpoints—such as PD-L1, PD-1 and CTLA-4—have introduced a major breakthrough in cancer therapy, with relatively good impact on disease course, primarily in melanoma [6,7].